173 related articles for article (PubMed ID: 31445426)
1. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.
Brusselaers N; Lagergren J; Engstrand L
Cancer Epidemiol; 2019 Oct; 62():101585. PubMed ID: 31445426
[TBL] [Abstract][Full Text] [Related]
2. Maintenance proton pump inhibition therapy and risk of oesophageal cancer.
Brusselaers N; Engstrand L; Lagergren J
Cancer Epidemiol; 2018 Apr; 53():172-177. PubMed ID: 29477057
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
4. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.
García Rodríguez LA; Lagergren J; Lindblad M
Gut; 2006 Nov; 55(11):1538-44. PubMed ID: 16785284
[TBL] [Abstract][Full Text] [Related]
5. Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy.
Holmberg D; Mattsson F; Xie S; Ness-Jensen E; El-Serag H; Lagergren J
J Gastroenterol; 2022 Dec; 57(12):942-951. PubMed ID: 36258093
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden.
Chandanos E; Lindblad M; Jia C; Rubio CA; Ye W; Lagergren J
Br J Cancer; 2006 Jul; 95(1):118-22. PubMed ID: 16755290
[TBL] [Abstract][Full Text] [Related]
7. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis.
Tran-Duy A; Spaetgens B; Hoes AW; de Wit NJ; Stehouwer CD
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1706-1719.e5. PubMed ID: 27211501
[TBL] [Abstract][Full Text] [Related]
8. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for
Cheung KS; Chan EW; Wong AYS; Chen L; Wong ICK; Leung WK
Gut; 2018 Jan; 67(1):28-35. PubMed ID: 29089382
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.
Waldum HL; Sørdal Ø; Fossmark R
Scand J Gastroenterol; 2018 Jun; 53(6):639-642. PubMed ID: 29852782
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors and risk of gastric cancer: population-based cohort study.
Abrahami D; McDonald EG; Schnitzer ME; Barkun AN; Suissa S; Azoulay L
Gut; 2022 Jan; 71(1):16-24. PubMed ID: 34226290
[TBL] [Abstract][Full Text] [Related]
12. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review and meta-analysis.
Peng TR; Wu TW; Li CH
Int J Clin Oncol; 2023 Jan; 28(1):99-109. PubMed ID: 36224477
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.
Hvid-Jensen F; Pedersen L; Funch-Jensen P; Drewes AM
Aliment Pharmacol Ther; 2014 May; 39(9):984-91. PubMed ID: 24617286
[TBL] [Abstract][Full Text] [Related]
14. Risk of gastric cancer among long-term proton pump inhibitor users: a population-based cohort study.
Kim JW; Jung HK; Lee B; Shin CM; Gong EJ; Hong J; Youn YH; Lee KJ
Eur J Clin Pharmacol; 2023 Dec; 79(12):1699-1708. PubMed ID: 37861752
[TBL] [Abstract][Full Text] [Related]
15. Gastric carcinoids after long-term use of a proton pump inhibitor.
Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
[TBL] [Abstract][Full Text] [Related]
16. Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis.
Jiang K; Jiang X; Wen Y; Liao L; Liu FB
J Gastroenterol Hepatol; 2019 Nov; 34(11):1898-1905. PubMed ID: 31206764
[TBL] [Abstract][Full Text] [Related]
17. Intake of Proton-Pump Inhibitors and Gastric Cancer within the Stomach Cancer Pooling (StoP) Project.
Sassano M; Mariani M; Pelucchi C; Lunet N; Morais S; Martín V; Moreno V; Curado MP; Dias-Neto E; Leja M; Gašenko E; La Vecchia C; Boccia S; Pastorino R
Cancer Epidemiol Biomarkers Prev; 2023 Sep; 32(9):1174-1181. PubMed ID: 37364052
[TBL] [Abstract][Full Text] [Related]
18. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux.
Vaughan TL; Farrow DC; Hansten PD; Chow WH; Gammon MD; Risch HA; Stanford JL; Schoenberg JB; Mayne ST; Rotterdam H; Dubrow R; Ahsan H; West AB; Blot WJ; Fraumeni JF
Cancer Epidemiol Biomarkers Prev; 1998 Sep; 7(9):749-56. PubMed ID: 9752982
[TBL] [Abstract][Full Text] [Related]
19. Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus.
Colin-Jones DG; Langman MJ; Lawson DH; Logan RF; Paterson KR; Vessey MP
Q J Med; 1991 Jan; 78(285):13-9. PubMed ID: 1670060
[TBL] [Abstract][Full Text] [Related]
20. Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia.
Ye W; Nyrén O
Gut; 2003 Jul; 52(7):938-41. PubMed ID: 12801947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
